Castration-resistant Prostate Cancer, Drug, Prostate Cancer
Conditions
Keywords
abiraterone, docetaxel, Castration-resistant Prostate Cancer
Brief summary
Metastatic castration-resistant Prostate cancer (mCRPC) is a very late stage of prostate cancer with poor prognosis. Although there are several treatment strategies available for mCRPC, these drugs are not always effective for every patient. Also, it's still not clear what's the best therapeutic choice for a certain group of patients. In the previous works of the investigators, a subtype of prostate cancer, intraductal carcinoma of the prostate (IDC-P) was studied. The investigators have reported in their two published papers that, IDC-P is an adverse pathological type associated with rapid disease progression. They also found in another study that, for patients with IDC-P, Abiraterone seemed to have better treatment efficacy than Docetaxel-based chemotherapy as first-line treatment for mCRPC, in terms of either PSA-response and PSA-progression free survival. So, in this study, the investigators hope to design a prospective study to verify the predictive ability of IDC-P in the first-line treatment of mCRPC. With disease progression, the drug resistance will inevitably occur in all patients after the treatment of CRPC. However, the exact mechanism of this process is not yet known. So, in this study the investigators are also trying to explore some of the genes related to the treatment efficacy by means of the next generation sequencing.
Interventions
DRUGDocetaxel
Docetaxel: intravenously, 75 mg/m\^2, over 1 h every 3 weeks, plus with prednisone, orally, 10 mg, qd. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs. If no progression, stop until 10 cycles of traetment
DRUGAbiraterone Acetate
Abiraterone Acetate: orally, 1000mg, qd, plus with prednisone orally, 5mg, bid. Course of treatment: Stop the treatment until biochemical, clinical or radiographic progression occurs.
Sponsors
West China Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Masking description
The administration methods of the two groups are different, therefore, the investigators decide not to use masking.
Eligibility
Sex/Gender
MALE
Age
40 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age: ≥40 years old 2. Positive IDC-P status confirmed by pathological examination. 3. Bone or visceral metastatic disease confirmed by image examination. 4. Castration resistant confirmed according to the criteria of 2014 EAU guidelines. 5. The ECOG score of the patient is ≤1 6. Expected survival over 3 months 7. Blood routine test: neutrophil ≥1.5 × 10\^9, platelets \>100 × 10\^9 and hemoglobin ≥90g/L 8. Blood biochemical indexes: bilirubin≤1.5×Upper limit of normal; AST≤2.5×Upper limit of normal; serum creatinine≤1.5×Upper limit of normal; serum calcium≤12.0mg/dL. 9. Coagulation function: Prothrombin time ≤1.5×Upper limit of normal 10. The following diseases were not found within 12 months: myocardial infarction, severe or unstable angina pectoris, asymptomatic heart failure, cardiovascular and cerebrovascular accident or transient ischemic attack, etc. 11. All patients should sign informed consent.
Exclusion criteria
1. Patients who had other types of cancer besides prostate cancer were excluded. 2. Patients With non-acinar adenocarcinoma except intraductal carcinoma of the prostate, including ductal adenocarcinoma, neuroendocrine carcinoma or small cell carcinoma of the prostate. 3. Prior chemotherapy or abiraterone for the treatment of mCRPC. 4. Patients with renal decompensation requiring hemodialysis or peritoneal dialysis. 5. Patients with severe active clinical infection 6. Patients with coagulopathy or bleeding 7. Patients who received major surgery or severe trauma within the first 4 weeks before admission. 8. Patients with a history of allogeneic organ transplantation or bone marrow transplantation 9. Patients with known or suspected allergy to research drugs.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| PSA-Progression free survival (PSA-PFS) | Up to 40 months | PSA progression was defined as an increase in the PSA level of 25% or more above the nadir (and by ≥ 2 ng/ml), with confirmation of 4 or more weeks later. |
| Radiographic progression free survival (rPFS) | Up to 40 months | rPFS was defined 1) according to the Response Evaluation Criteria in Solid Tumors (RECIST) v.1.1 criteria; or 2) as at least two new lesions on first post-treatment bone scan, with at least two additional lesions on the next bone scan. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| PSA response rate | Up to 40 months | PSA response is defined as ≥ 50% decline in PSA level from baseline, maintained for≥ 4 weeks |
| Overall survival (OS) | Up to 40 months | OS was defined as the duration from the initiation of treatment to death of any cause |
| Eastern Cooperative Oncology Group (ECOG) score | Up to 40 months | 0 - Fully active, able to carry on all pre-disease performance without restriction; 1. \- Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g. light house work, office work; 2. \- Ambulatory and capable of all self-care but unable to carry out any work activities. Up and about more than 50% of waking hours; 3. \- Capable of only limited self-care, confined to bed or chair more than 50% of waking hours; 4. \- Completely disabled. Cannot carry out on any self-care; totally confined to bed or chair. |
Outcome results
None listed